The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorisation for Ipsen’s investigational palovarotene as a treatment for fibrodysplasia ossificans progressiva (FOP).   The company says it will be requesting a re-examination of the CHMP opinion, based on scientific data available from the existing […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!